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Abstract
We report the first published case of etravirine induced hypersensitivity reaction leading to fulminant hepatic
failure in a 49-year-old female patient with Human Immunodeficiency Virus. She presented with a life threatening
rash and end stage organ damage requiring intensive care unit supportive care. Liver biopsy supported the diagnosis
of drug-induced hypersensitivity. The patient recovered after withdrawal of etravirine and the use of systemic
corticosteroids. The authors describe etravirine drug hypersensitivity as a clinically important reaction and that early
recognition can improve survival.
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Introduction
Etravirine is a second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used in treatment-experienced patients or patients with drug resistant Human Immunodeficiency Virus (HIV). In
a pooled analysis of phase III trials, etravirine demonstrated a favorable safety profile compared with control with the exception of rash reported more frequently with etravirine than placebo, 21% versus 12%,
respectively [1,2].
Despite etravirine’s safety profile in clinical trials, several post-marketing reports of severe skin reactions which include hypersensitivity
reactions resulting in hepatic failure have recently been identified. As
a result, Janssen Therapeutics, formerly Tibotec Pharmaceuticals, and
the Food and Drug Administration issued a letter informing healthcare
professionals of such findings [3,4]. To date, we report the first case of a
life threatening hypersensitivity reaction to etravirine resulting in rash
and fulminant hepatic failure.

Observation
A 49-year-old African American woman with HIV and resolved
hepatitis B had been taking highly active antiretroviral therapy
(HAART) for over 10 years. She had adverse reactions to indinavir,
nelfinavir, abacavir, efavirenz, nevirapine and tenofovir and her antiretroviral therapy (ART) had been limited to didanosine and stavudine. With the approval of etravirine and raltegravir, the patient’s ART
was changed to etravirine 200 mg, raltegravir 400 mg, and lopinavir/
ritonavir 400 mg/100 mg each given twice daily. Her baseline CD4
count was 216 cells/mL and her viral load was 902 copies/mL prior
to the initiation of this regimen. Liver function tests, complete blood
counts, and electrolytes were within normal limits. She was not on any
other medications or herbal supplements. She also denied alcohol use.
Three weeks after beginning her new HAART, she developed a diffuse
maculopapular rash. Despite discontinuation of the antiretroviral therapy, her rash progressed with involvement of her entire body and she
developed fever, jaundice, emesis, and diarrhea. Physical examination
revealed a febrile, encephalopathic and severely jaundiced patient with
a diffuse maculopapular rash on the face, chest, abdomen, and extremities sparing her mucous membranes, with early signs of desquamation.
She had hepatomegaly and right upper quadrant tenderness.
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Laboratory studies on admission revealed a white blood cell count
of 13.3 x 103/μL with 10% eosinophils (normal, 0-5%) and absolute
eosinophils 1.3 x 103 cells/μL (normal, 0-0.65 x 103 cells/μL). Liver
enzyme peak values were aspartate transaminase 2364 IU/L, alanine
transaminase 1174 IU/L, total bilirubin 19.4 mg/dL, and INR 3.05 on
her day of hospitalization. Acute hepatitis panel for Hepatitis A, B, and
C were negative. Hepatitis B Viral DNA PCR was undetectable and
Hepatitis C RNA PCR was less than 50 IU/mL. HIV-1 RNA quantitative PCR was less than 48 copies/mL. A urine toxicology screen was
negative for acetaminophen. Except for hepatomegaly, an abdominal
ultrasound was unremarkable for liver lesions and showed a patent hepatic vasculature. A transjugular liver biopsy showed confluent multiacinar hepatic necrosis with portal mixed inflammatory infiltrates including eosinophils, activated lymphocytes and plasma cells suggestive
of a drug induced etiology (Figure 1).
She was considered for liver transplant due to fulminant and
worsening hepatic failure. She was managed in the intensive care unit
with aggressive fluid-electrolyte management, empiric antibiotics, rifaximin and lactulose. However she only improved after intravenous
methylprednisolone was administered. After which, she made a slow
but steady recovery. Because of her significant improvement, she did
not need a liver transplant and was discharged home after fifteen days
of hospitalization. Her liver function tests normalized six weeks after
etravirine was discontinued.

Discussion
Our case report underscores the importance of recognizing drug
induced hypersensitivity syndrome (DHS) from etravirine use. DHS,
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between the offending drug and liver damage. Application to our case
showed a causality of this adverse drug reaction using the RUCAM/
CIOMS scale of seven or “probable” adverse reaction [13,14].

Figure 1: A hepatic biopsy showing confluent multi acinar hepatic necrosis with
portal mixed inflammatory infiltrates including eosinophils, activated lymphocytes and plasma cells suggestive of drug induced etiology.

also known as drug rash with eosinophilia and systemic symptoms, is
characterized by exfoliative dermatitis, fever and potentially life threatening end organ damage [5,6]. Severe DHS has been reported in less
than 2% of all HIV-infected individuals treated with NNRTIs and most
commonly described with nevirapine use [7,8,9]. In clinical practice,
severe cutaneous reactions appear to be less common with efavirenz
than with nevirapine. The incidence of DHS in efavirenz is 0.14% in all
studies [10]. Rilpivirine licensure was recently approved in May, 2011.
To date, no cases of rilpivirine associated DHS have been reported.
The primary cause of mortality in DHS is fulminant hepatic failure,
occurring between 1 and 6 weeks after the initiation of drug therapy
and often necessitates liver transplant [11,12]. Our patient presented
with an exfoliative rash, eosinophilia, and hepatic failure approximately 3 weeks after initiation of etravirine. Histopathologic findings
on liver biopsy associated with DHS include necrosis, cholestasis, and
eosinophilic infiltration, as was seen in our case [5].
DHS caused by nevirapine has been well documented in the literature. Historically, this adverse reaction has been associated in women
with CD4 counts greater than 250 cells/mm3 and men with CD4 counts
greater than 400 cells/mm3. Liver biopsy results in these patients have
found eosinophilic and lymphocytic infiltration consistent with an
immune mediated mechanism and frequently necrosis. Based on the
case reports of nevirapine induced liver injury, the median onset of
symptoms is typically 14 days and the median time to improvement
is 21.5 days [8,9,12]. Our case is similar to DHS caused by nevirapine
in several ways. First, our patient presented with severe rash and fulminant hepatic failure 21 days into initiation of her etravirine based
regimen. Second, her liver biopsy was similar to the pattern seen with
nevirapine hepatotoxicity. Finally, her liver function tests normalized
within 6 weeks of etravirine withdrawal, which is similar to the timeframe of resolution of nevirapine induced hepatitis. Our patient previously had a rash to both the NNRTIs, efavirenz and nevirapine without
hepatoxicity. It remains to be elucidated if adverse reactions from prior
exposure to NNRTIs poses a risk factor for DHS and should not be
overlooked.
The Roussel Uclaf Causality Assessment Method of the Council for
International Organizations of Medical Sciences (RUCAM/CIOMS) is
one of the most widely used scales for establishing a causal relationship
J AIDS Clinic Res

Our patient was also on raltegravir and lopinavir/ritonavir. Raltegravir is generally a well-tolerated HIV-1 integrase inhibitor. A review
of the current literature through PubMED shows limited data on the
toxicity and side effects of this medication. A common adverse effect
with raltegravir use is elevated alkaline phosphatase levels, which can
range between 2.6 to five times the upper limit of normal [15,16]. Elevated creatinine phosphokinase levels in association with myopathy
and rhabdomyolysis have also been reported [17]. In November 2011,
the FDA added rash and hypersensitivity reaction to the warning and
precaution section of raltegravir [16]. However our patient was rechallenged with raltegravir after hospital discharge and has been on
raltegravir for over one year without any adverse reaction. Lopinavir/
ritonavir combination has been associated with mild to moderate hepatic impairment and this is usually limited to patients with Hepatitis
C viremia and baseline hepatic insufficiency [18]. Lopinavir/ritonavir
has rarely been associated with drug hypersensitivity reaction. We excluded lopinavir/ritonavir as the offending drug in our patient as she
tolerated it in the past without any rash or liver abnormalities.
Our case was one of first post-licensure reports of etravirine induced hypersensitivity reaction with hepatic failure. A request to Janssen Therapeutics for details on the additional reported hypersensitivity
cases presented in the etravirine investigator’s brochure was declined
at this time. We searched medline through PubMed using the words
etravirine, hypersensitivity, Stevens Johnson syndrome and toxic epidermal necrolysis to look for cases of hypersensitivity reaction and end
organ failure. To the best of our knowledge, this is the first published
case report of etravirine induced drug hypersensitivity reaction. If not
recognized with prompt removal of the offending agent, DHS can lead
to significant morbidity and mortality. Early administration of intravenous corticosteroids may be beneficial and may improve patient outcome [11,19].
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